



January 8, 2026

Company Name: GNI Group Ltd.
Representative: Director, Representative Executive Officer,
President and CEO
Ying Luo, PhD
(Security Code: 2160, TSE Growth)
Contact Person: Director, Executive Officer, Vice President
COO and CFO
Ryosuke Matsui
(TEL. 03-6214-3600)

Cullgen's Participation in the J.P. Morgan Healthcare Conference

(Note) This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the Japanese original shall prevail.

GNI Group Ltd. announces that its consolidated subsidiary, Cullgen Inc. ("Cullgen"), has announced its participation in the 44th Annual J.P. Morgan Healthcare Conference to be held in San Francisco, California, United States, from January 12, 2026.

The J.P. Morgan Healthcare Conference is one of the largest healthcare-focused investor conferences, bringing together investors and senior executives from hundreds of healthcare companies worldwide.

Cullgen has also released its latest corporate presentation.

<https://www.cullgen.com/about-us>

The presentation highlights the following development updates:

- A novel non-opioid pain product candidate, CG001419, is anticipated to begin a Phase 2 clinical trial during the second quarter of 2026.
- A new targeted protein degrader development program for inflammatory diseases has been added to the updated pipeline and has advanced into IND-enabling studies.

[Conference Details]

Press release issued by Cullgen Inc.

[Cullgen Announces Conference Participation JPM — Cullgen](#)